5-(2,3-环氧丙氧基)-3,4-二氢喹诺酮 | 51781-14-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-(2,3-环氧丙氧基)-3,4-二氢喹诺酮
• 中文别名: 盐酸卡替洛尔EP杂质C
• 英文名称: 5-(2,3-epoxypropoxy)-3,4-dihydro-2 (1H)-quinolone
• 英文别名: 5-(2,3-epoxy)propoxy-3,4-dihydrocarbostyril；5-oxiranylmethoxy-3,4-dihydro-1H-quinolin-2-one；1-(3,4-dihydrocarbostyril-5-yloxy)-2,3-epoxypropane；3,4-dihydro-5-(2,3-epoxypropoxy)-2-(1H)-quinolinone；5-(2,3-epoxypropoxy)-3,4-dihydro-2-quinolinone；5-(2,3-epoxy-propoxy)-3,4-dihydro-carbostyril；5-(2,3-Epoxypropoxy)-3,4-dihydrocarbostyril；5-(oxiran-2-ylmethoxy)-3,4-dihydro-1H-quinolin-2-one
• CAS: 51781-14-7
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: VQTWQOBNPISQPG-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿、可溶于二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.35
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  50.86
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  5-(2,3-环氧丙氧基)-3,4-二氢喹诺酮 生成 7-{3-[4-(3-fluoro-phenyl)-piperazin-1-yl]-propoxy}-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  BANNO, KAZUO;FUJIOKA, TAKAFUMI;OSHIRO, YASUO;NAKAGAWA, KAZUYUKI

  摘要：

  DOI：
• 作为产物：
  描述：

  5-羟基-3,4-二氢-2-喹啉酮 、 环氧溴丙烷 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 5-(2,3-环氧丙氧基)-3,4-二氢喹诺酮
  参考文献：
  名称：

  3,4-Dihydrocarbostyril derivatives and process for producing the same

  摘要：

  所表示的新化合物，其分子式为##STR1##，其中R.sup.1、R.sup.2和R'以及R"的定义如下，具有阻断β-肾上腺素神经的活性，新的中间体对合成有所帮助，以及制备这些化合物的过程。当取代位置在5位且R.sup.1和R.sup.2为氢时，所申请的化合物中R'和R"不能同时为氢和1到4个碳原子的烷基团。

  公开号：

  US04256890A1

文献信息

• Derivatives of 3-aminopropane-1,2-diol
  申请人：Ciba-Geigy Corporation

  公开号：US04497813A1

  公开（公告）日：1985-02-05

  Derivatives of 3-aminopropane-1,2-diol of the formula ##STR1## in which Ar represents optionally substituted aryl, n represents the number 0 or 1, and alk represents alkylene having 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom, or, if n is zero, the phenyl radical, being separated from one another by at least two carbon atoms, and R.sub.1 and R.sub.2, independently of one another, each represents hydrogen or lower alkyl, or together they represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene, and salts of such compounds, processes for their manufacture, medicaments containing the new compounds and their use for the treatment of Angina pectoris and cardiac arrhythmia, and as blood pressure-reducing agents, as well as for the treatment of reactive or endogenic states of depression.

  3-氨基丙烷-1,2-二醇的衍生物的化学式为##STR1##其中Ar代表可选择取代的芳基，n代表数字0或1，alk代表具有2至5个碳原子的烷基，氮原子和氧原子，或者如果n为零，则苯基与彼此至少相隔两个碳原子，而R.sub.1和R.sub.2，彼此独立地，每个代表氢或较低的烷基，或者它们一起代表较低的烷基，氧杂环较低的烷基，硫杂环较低的烷基，氮杂环较低的烷基或N-较低烷基-氮杂环较低的烷基，以及这类化合物的盐，其制备方法，含有新化合物的药物以及它们用于治疗心绞痛和心律失常，以及作为降血压剂，以及用于治疗反应性或内源性抑郁状态。
• Compounds enhancing antitumor activity of other cytotoxic agents
  申请人：Pfizer Inc

  公开号：US06130217A1

  公开（公告）日：2000-10-10

  This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

  这项发明涉及某些杂环化合物及其药用可接受的盐，这些化合物对于使多药耐药肿瘤细胞对抗癌药物和多药耐药形式的疟疾、结核病、利什曼病和阿米巴痢疾对化疗药物具有敏感性是有用的。这些化合物及其药用可接受的盐还是人类MDR1基因编码的P-糖蛋白的活性药物转运能力的抑制剂，以及来自真核和原核生物（例如，来自疟原虫的pfmdr，以及小鼠mdr1和mdr3基因产物）的某些其他相关的ATP结合盒转运蛋白的抑制剂。
• Aryloxypropanolaminotetralins, a process for their preparation and
  申请人：Elf Sanofi

  公开号：US05254595A1

  公开（公告）日：1993-10-19

  Aryloxypropanolaminotetralins with beta-antagonist activity of the formula ##STR1## wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described. A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.

  具有β-阻断活性的芳氧基丙醇胺四氢萘，其通式为##STR1##，其中R为氢、羟基或甲氧基，Ar为可选择性取代的芳香或杂芳香基团，以光学活性或非活性形式及其酸加成盐被描述。它们的制备方法以及含有通式(i)化合物或其药学上可接受的酸加成盐的药物组合物也被描述。
• Studies on Agents with Vasodilator and ,B-Blocking Activities. IV.
  作者：Toshimi SEKI、Tomio NAKAO、Takeshi MASUDA、Kohichi HASUMI、Kotaro GOTANDA、Tsutomu ISHIMORI、Seijiro HONMA、Nobuyoshi MINAMI、Kenyu SHIBATA、Kikuo YASUDA

  DOI：10.1248/cpb.44.2061

  日期：——

  A series of novel pyridazinone derivatives (II) having a phenoxypropanolamine moiety was synthesized. Their hypotensive and β-blocking activities were evaluated after intravenous administration of the compounds to anesthetized rats. Among them, the 5-chloro-2-cyanophenoxy derivative (29) showed the promising dual activities and was selected for further studies.

  合成了一系列具有苯氧基丙醇胺结构的新型哒嗪酮衍生物（II）。在静脉注射给麻醉大鼠后，评估了它们的降压和β-阻断活性。其中，5-氯-2-氰基苯氧基衍生物（29）显示出有前途的双重活性，并被选中进行进一步研究。
• Cardiotonic and antithrombotic sulfur-containing derivatives of
  申请人：Boehringer Ingelheim GmbH

  公开号：US04329347A1

  公开（公告）日：1982-05-11

  Compounds of the formula ##STR1## wherein W is vinylene, methyl-vinylene, methylene or ethylene; m is 0, 1 or 2; D is straight or branched alkylene of 2 to 6 carbon atoms, straight or branched hydroxy-alkylene of 3 to 6 carbon atoms, or xylylene; R.sub.1 is hydrogen or alkyl of 1 to 3 carbon atoms; R.sub.2 is cycloalkyl of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, aralkyl of 7 to 11 carbon atoms, heteroaryl, heteroarlkyl, 1,2,4-triazolyl, triphenylmethyl, 4,5-bis-(p-chlorophenyl)-oxazol-2-yl, N-methyl-cyclohexylamino-carbonylmethyl,-amino-iminomethyl or, when m is 1 or D is hydroxyalkylene or xylylene, also alkyl of 1 to 6 carbon atoms; and R.sub.3 and R.sub.4 are each hydrogen, halogen, alkyl of 1 to 4 carbon atoms, amino, acetylamino or nitro. The compounds of the invention are useful as cardiotonics and as antithrombotics.

  式为##STR1##的化合物，其中W为乙烯基、甲基乙烯基、亚甲基或乙烯基；m为0、1或2；D为2至6个碳原子的直链或支链烷基、3至6个碳原子的直链或支链羟基烷基，或二甲苯基；R.sub.1为氢或1至3个碳原子的烷基；R.sub.2为3至6个碳原子的环烷基、6至10个碳原子的芳基、7至11个碳原子的芳基烷基、杂环芳基、杂环芳基烷基、1,2,4-三唑基、三苯甲基、4,5-双-(对氯苯基)-噁唑-2-基、N-甲基环己基氨基甲酰甲基、氨基亚甲基或当m为1或D为羟基烷基或二甲苯基时，也为1至6个碳原子的烷基；以及R.sub.3和R.sub.4分别为氢、卤素、1至4个碳原子的烷基、氨基、乙酰氨基或硝基。本发明的化合物可用作心力衰竭药和抗血栓药。